PI3K

Phosphoinositide 3-kinases (PI3Ks) are lipid kinases that catalyze the phosphorylation of phosphatidylinositol 4,5-bisphosphate (PI(4,5)P₂) to generate the second messenger phosphatidylinositol (3,4,5)-trisphosphate (PI(3,4,5)P₃). The production of PI(3,4,5)P₃ facilitates the recruitment and activation of pleckstrin homology (PH) domain–containing proteins at the plasma membrane, thereby initiating downstream signaling cascades essential for cellular proliferation, survival, and migration.

PI3Ks are divided into three major classes, among which Class I PI3Ks are most prominently implicated in cancer biology. Class I enzymes comprise four distinct catalytic isoforms: PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ.

Class IA PI3Ks, the subclass most commonly associated with oncogenic signaling, function as heterodimeric lipid kinases composed of a catalytic p110 subunit (p110α, p110β, or p110δ, encoded by PIK3CA, PIK3CB, and PIK3CD, respectively) and a regulatory p85 subunit.

The PI3K signaling pathway plays a central role in diverse biological processes, including cell cycle progression, cellular growth, survival, actin cytoskeletal rearrangement, migration, and intracellular vesicular trafficking.

Frequently Asked Questions
Phosphoinositide 3-kinases (PI3Ks) are a family of lipid kinases that phosphorylate phosphatidylinositol lipids to regulate cell growth, survival, metabolism, and immune signaling. PI3K activation leads to downstream AKT and mTOR pathway signaling. Aberrant PI3K signaling is frequently observed in cancer due to PIK3CA mutations, PTEN loss, or receptor tyrosine kinase activation.
Class I PI3Ks include four catalytic isoforms: PI3Kα (PIK3CA) PI3Kβ (PIK3CB) PI3Kδ (PIK3CD) PI3Kγ (PIK3CG) PI3Kα and β are broadly expressed, while PI3Kδ and γ are enriched in leukocytes and play critical roles in immune regulation. Isoform selectivity is an important consideration in drug development due to toxicity and immune effects.
PI3K inhibitors can be classified as: Pan-PI3K inhibitors Isoform-selective inhibitors (α, β, δ, γ) Dual PI3K/mTOR inhibitors Irreversible inhibitors Selectivity influences therapeutic window and toxicity profile.
While PI3K inhibitors block upstream lipid kinase activity, mTOR inhibitors act downstream at the level of mTORC1 or mTORC2. Dual PI3K/mTOR inhibitors target both nodes of the pathway and may achieve broader pathway suppression.

Items 51-75 of 369

  • Sonolisib
    Cat. No.
    A11261

    Sonolisib (PX-866)

    Synonyms: PX866

    PX-866 is a small-molecule wortmannin analogue inhibitor of the alpha, gamma, and delta isoforms of phosphoinositide 3-kinase (PI3K) with potential antineoplastic activity.

    5 mg
    $355.00
    10 mg
    $600.00
    All 4 sizes
  • Dactolisib Tosylate
    Cat. No.
    A11327

    Dactolisib Tosylate

    Synonyms: BEZ235 (Tosylate); NVP-BEZ 235 (Tosylate)

    Dactolisib Tosylate (BEZ235 Tosylate) is a dual PI3K and mTOR kinase inhibitor with IC50 values of 4, 75, 7, 5 nM for PI3Kα, β, γ, δ, respectively. Dactolisib Tosylate (BEZ235 Tosylate) inhibits mTORC1 and mTORC2.

    25 mg
    $35.00
    50 mg
    $50.00
    All 6 sizes
  • Pictilisib dimethanesulfonate
    Cat. No.
    A11444

    Pictilisib dimethanesulfonate

    Synonyms: GDC-0941 dimethanesulfonate; GDC-0941 2 MeSO3H salt

    Pictilisib dimethanesulfonate (GDC-0941 dimethanesulfonate) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold).

    5 mg
    $20.00
    10 mg
    $25.00
    All 8 sizes
  • NVP-BAG956
    Cat. No.
    A11511

    NVP-BAG956

    NVP-BAG956 acts as a potent, reversible, and ATP-competitive PI 3-K/PDK1 dual kinase inhibitor, displaying much reduced potency against VEGFR1 (IC50 = 2.56 uM) and little or no activity toward a panel of 15 other kinases (IC50 >10 uM).

    1 mg
    $45.00
    5 mg
    $115.00
    All 8 sizes
  • TG 100713
    Cat. No.
    A11956

    TG 100713

    TG 100713 is an inhibitor of PI3-kinase that inhibits endothelial cell proliferation.

    5 mg
    $25.00
    10 mg
    $45.00
    All 5 sizes
  • Zandelisib
    Cat. No.
    A12273

    Zandelisib

    Synonyms: ME-401; PWT-143

    Zandelisib is a selective, orally active, non-covalent inhibitor of PI3Kδ. It effectively inhibits AKT phosphorylation and suppresses downstream signaling pathways, making it a valuable tool in cancer research. Zandelisib is particularly relevant for studying malignancies such as relapsed or refractory B-cell lymphoma, providing insights into tumor behavior and therapeutic response.

    1 mg
    $60.00
    5 mg
    $155.00
    All 6 sizes
  • Duvelisib
    Cat. No.
    A12422

    Duvelisib (IPI-145, INK1197)

    Synonyms: IPI145; IPI-145. INK-1197; INK 1197

    IPI-145, also known as INK-1197, is an orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities.

    2 mg
    $35.00
    5 mg
    $55.00
    All 7 sizes
  • VS-5584
    Cat. No.
    A12480

    VS-5584

    Synonyms: SB2343

    VS-5584 is a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer.

    5 mg
    $25.00
    10 mg
    $45.00
    All 7 sizes
  • SF1126
    Cat. No.
    A12704

    SF1126

    SF1126 is a water soluble, small-molecule prodrug containing the pan-PI3K/mTOR inhibitor LY294002/SF1101 conjugated to the RGD-containing tetra-peptide SF1174 with potential antineoplastic and antiangiogenic activities.

    1 mg
    $380.00
    5 mg
    $960.00
    All 6 sizes
  • PF-4989216
    Cat. No.
    A12889

    PF-4989216

    PF-4989216 is a potent and selective PI3K inhibitor with IC50 of 2 nM, 142 nM, 65 nM, 1 nM, and 110 nM for p110α, p110β, p110γ, p110δ, and VPS34, respectively.

    2 mg
    $25.00
    5 mg
    $50.00
    All 8 sizes
  • PF-04979064
    Cat. No.
    A12935

    PF-04979064

    Synonyms: PF049790

    PF-04979064 is a highly potent and orally bioavailable PI3K/mTOR dual inhibitor.

    2 mg
    $20.00
    5 mg
    $30.00
    All 4 sizes
  • GS-9901
    Cat. No.
    A12988

    GS-9901

    GS-9901 is a highly selective and orally active PI3Kδ inhibitor, with an IC50 of 1 nM. Has potential to treat rheumatoid arthritis.

    1 mg
    $75.00
    5 mg
    $190.00
    All 7 sizes
  • Parsaclisib
    Cat. No.
    A13561

    Parsaclisib

    Synonyms: INCB050465

    Parsaclisib is a potent and selective PI3Kδ inhibitor, with an IC50 of 1 nM at 1 mM ATP, and shows appr 20,000-fold selectivity for PI3Kα, PI3Kβ, PI3Kγ and 57 other kinases.

    1 mg
    $140.00
    5 mg
    $275.00
    All 7 sizes
  • CNX-1351
    Cat. No.
    A13879

    CNX-1351

    CNX-1351 is a potent and isoform-selective targeted covalent PI3Kα inhibitor with IC50 of 6.8 nM.

    1 mg
    $35.00
    5 mg
    $85.00
    All 7 sizes
  • GNE-317
    Cat. No.
    A13992

    GNE-317

    GNE-317 is a potent PI3K inhibitor that can cross the Blood, brain barrier; shows potent suppression of the PI3K pathway in the brain of mice with intact BBB.

    1 mg
    $25.00
    2 mg
    $40.00
    All 9 sizes
  • GNE 477
    Cat. No.
    A14114

    GNE 477

    Synonyms: GNE-477,GNE477

    GNE-477 is a potent and efficacious dual PI3K/mTOR inhibitor with IC50 of 4 nM for PI3Kα, Kiapp is 21 nM for mTOR.

    1 mg
    $55.00
    2 mg
    $85.00
    All 8 sizes
  • Miltefosine
    Cat. No.
    A14138

    Miltefosine

    Synonyms: HePC

    Miltefosine inhibits PI3K/Akt activity with ED50 of 17.2 μM and 8.1 μM in carcinoma cell lines A431 and HeLa

    50 mg
    $40.00
    100 mg
    $45.00
    All 6 sizes
  • (Rac)-AZD8186
    Cat. No.
    A14164

    (Rac)-AZD8186

    Synonyms: AZD-8186

    (Rac)-AZD8186 is and inhibitor of the beta isoform of phosphoinositide-3 kinase (PI3K), with potential antineoplastic activity.

    5 mg
    $150.00
    10 mg
    $250.00
    All 3 sizes
  • NVP-BBD130
    Cat. No.
    A14425

    NVP-BBD130

    NVP-BBD130 is a potent dual inhibitor of PI3K and mTOR, functioning through ATP-competitive mechanisms. This compound demonstrates significant stability and provides effective oral bioavailability. Additionally, NVP-BBD130 serves as a click chemistry reagent due to its alkyne group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. Its versatility makes it suitable for various research applications in cancer therapy and biochemical signaling pathways.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • GNE-493
    Cat. No.
    A14432

    GNE-493

    GNE-493 is potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitor with potential anticancer activity.

    1 mg
    $35.00
    5 mg
    $100.00
    All 7 sizes
  • Acalisib
    Cat. No.
    A14441

    Acalisib (GS-9820)

    Synonyms: GS-9820

    Acalisib is an inhibitor of the beta and delta isoforms of the 110 kDa catalytic subunit of class IA phosphoinositide-3 kinases (PI3K) with potential immunomodulating and antineoplastic activities.

    1 mg
    $30.00
    5 mg
    $40.00
    All 8 sizes
  • CAL-130
    Cat. No.
    A15030

    CAL-130

    CAL-130 is a novel phosphoinositide 3-kinase (PI3K) inhibitor. It is reported that combined inhibition of PI3Kδ/γ as therapy for T cell acute lymphoblastic leukemia (T-ALL).

    5 mg
    $500.00
    10 mg
    $800.00
    All 5 sizes

Items 51-75 of 369

Added to your cart

View Cart Checkout

    Loading...